THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. State opioid response (SOR) Grant funding for FY24. Substance Abuse and Mental Health Block Grant (SABG) funding for FY24.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Health Issues HCR
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. State opioid response (SOR) Grant funding for FY24. Substance Abuse and Mental Health Block Grant (SABG) funding for FY24.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Aerospace AER
FAA reauthorization - increasing access to naloxone.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.